
Trump diagnosed with vein condition after noticing 'mild swelling' in his legs
Press secretary Karoline Leavitt said tests by the White House medical unit showed that Trump has chronic venous insufficiency, which occurs when little valves inside the veins that normally help move blood against gravity gradually lose the ability to work properly.
Leavitt also addressed bruising on the back of Trump's hand, seen in recent photos covered by makeup that was not an exact match to his skin tone.
She said the bruising was "consistent" with irritation from his "frequent handshaking and the use of aspirin." Trump takes aspirin to reduce the risk of heart attack and stroke.
During her press briefing, Leavitt said her disclosure of Trump's medical checkup was meant to dispel recent speculation about the 79-year-old Republican president's health. Nonetheless, the announcement was notable given that Trump has routinely kept secret basic facts about his health.
Trump in April had a comprehensive physical exam with more than a dozen medical specialists. The three-page report released then by the White House did not include a finding of chronic venous insufficiency.
At the time, his doctor determined that the president's joints and muscles had a full range of motion, with normal blood flow and no swelling.
Leavitt did not say when Trump first noticed the swelling in his lower legs. As part of the president's routine medical care and out of an "abundance of caution," she said he had a "comprehensive exam" that included vascular, lower extremity and ultrasound testing.
Common condition for those 70-plus: Leavitt
Leavitt noted that chronic venous insufficiency is a benign condition that is common in people over age 70.
She said the tests revealed no evidence of deep vein thrombosis, a more serious medical condition in which a blood clot forms in one or more of the deep veins in the body, usually in the legs. Nor was there any evidence of arterial disease, she said, reading a letter from Trump's doctor.
People are often advised to lose weight, walk for exercise and elevate their legs periodically, and some may be advised to wear compression stockings. Severe cases over time can lead to complications, including lower leg sores called ulcers. Blood clots are one cause, but they were ruled out, Leavitt said.
Leavitt said the condition wasn't causing the president any discomfort. She wouldn't discuss how he was treating the condition and suggested those details would be in the doctor's letter, which was later released to the public. But the letter was the same as what she read, and it did not include any additional details.
The exam the White House disclosed on Thursday included other testing that found no signs of heart failure, renal impairment or systemic illness, Leavitt said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CTV News
13 hours ago
- CTV News
Smoke from wildfires triggers special air quality statement in Ontario
A haze from the western wildfires as seen from Waterloo Region on June 5, 2025. The long weekend may be a smoky one for people in most of Ontario. Environment Canada issued a special air quality statement at 1:28 p.m. Saturday, warning of poor air quality and reduced visibility. 'Smoke from forest fires is expected to continue to spread south into southern Ontario this afternoon and evening. The wildfire smoke may persist for much of the weekend for parts of southern Ontario,' the notice read. The smoke is billowing from wildfires burning in the Prairies. Environment Canada warns air quality and visibility could fluctuate over short distances and vary 'considerably' from hour to hour. People living in the effected areas, including Waterloo Region, Wellington County, Brant County, Perth County and Oxford County, were encouraged to limit time outdoors and consider reducing or rescheduling outdoor activities. The weather office said some people are more likely to be impacted by the smoke, including people aged 65 or older, pregnant people, infants and young children, and people with pre-existing conditions. Anyone working outdoors for long periods of time could also feel the effects. Some people may experience eye, nose and throat irritation, headaches or a mild cough. Rare, but less common, symptoms include wheezing, chest pain and severe coughs.


CBC
16 hours ago
- CBC
Expert discusses potential impact of Trump's demand to slash drug prices in U.S.
U.S. President Donald Trump has issued a direct warning to top pharmaceutical companies, demanding they slash drug prices. Mina Tadrous, an associate professor at the University of Toronto's Leslie Dan Faculty of Pharmacy, discusses concerns and how this could impact drug prices in Canada.


Globe and Mail
18 hours ago
- Globe and Mail
AstraZeneca's AZD3427 Study: A Potential Game-Changer for Heart Failure and Pulmonary Hypertension
AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AstraZeneca, in collaboration with Parexel International, is conducting a Phase IIb study titled A Phase IIb Randomised, Double-blind, Placebo-controlled, Multi-centre, Dose-ranging Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Due to Left Heart Disease (WHO Group 2). The study aims to assess the efficacy of AZD3427 in reducing pulmonary vascular resistance in patients with heart failure and pulmonary hypertension over 24 weeks, highlighting its potential significance in treating these conditions. The intervention being tested is AZD3427, administered as a subcutaneous injection. It is designed to target pulmonary hypertension by reducing vascular resistance, with the study evaluating three different dose levels of the drug. The study follows a randomized, parallel assignment model with triple masking, involving participants, care providers, and investigators. Its primary purpose is treatment-focused, aiming to determine the optimal dosing strategy for AZD3427. The study began on April 24, 2023, with an estimated completion date in July 2025. These timelines are crucial for tracking the progress and potential market introduction of AZD3427. The outcome of this study could significantly impact AstraZeneca's market position, potentially boosting its stock performance if results are positive. Investors will be keenly watching for updates, especially in the context of competitive treatments for heart failure and pulmonary hypertension. The study is ongoing, with further details available on the ClinicalTrials portal.